The dose range for Lester is 1 mg to 4 mg orally once daily at any time of the day with or without food. The recommended starting dose is 2 mg and the maximum dose is 4 mg. The starting dose and maintenance doses of Lester should be individualized according to patient characteristics, such as goal of therapy and response.

After initiation or upon titration of Lester, lipid levels should be analyzed after 4 weeks and the dosage adjusted accordingly.

Dosage in Patients with Renal Impairment

Patients with moderate and severe renal impairment (glomerular filtration rate 30 mL/min/1.73 m2 to 59 mL/min/1.73 m2 and 15 mL/min/1.73 m2 to 29 mL/min/1.73 m2 not receiving hemodialysis, respectively) as well as end-stage renal disease receiving hemodialysis should receive a starting dose of Lester 1 mg once daily and a maximum dose of Lester 2 mg once daily.

Use with Erythromycin

In patients taking erythromycin, a dose of Lester 1 mg once daily should not be exceeded.

Use with Rifampin

In patients taking rifampin, a dose of Lester 2 mg once daily should not be exceeded.

More about Lester (Lester)

Side Effects
During Pregnancy or Breastfeeding
Dosage Information
Drug Interactions
Support Group
0 Reviews – Add your own review/rating
Drug class: statins

Consumer resources

Lester (Advanced Reading)

Other brands: Lester, Nikita

Professional resources

Lester (FDA)
Lester Calcium (AHFS Monograph)

Related treatment guides

Dyslipidemia
High Cholesterol

What other drugs will affect Lester?

Tell your doctor about all other medicines you use. Like Lester, certain other drugs can increase your risk of serious muscle problems, especially:

colchicine;
gemfibrozil;
fenofibric acid;
fenofibrate; or
medicines that contain niacin (Advicor, Niaspan, Niacor, Simcor, Slo-Niacin, and others).

This list is not complete. Other drugs may affect Lester, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Drug Interactions (in more detail)

Lester interactions

sponsored

Cyclosporine

Cyclosporine significantly increased Lester exposure. Co-administration of cyclosporine with Lester is contraindicated.

Erythromycin

Erythromycin significantly increased Lester exposure. In patients taking erythromycin, a dose of Lester 1 mg once daily should not be exceeded.

Rifampin

Rifampin significantly increased Lester exposure. In patients taking rifampin, a dose of Lester 2 mg once daily should not be exceeded.

Gemfibrozil

Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of Lester with gemfibrozil should be avoided.

Other Fibrates

Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, Lester should be administered with caution when used concomitantly with other fibrates.

Niacin

The risk of skeletal muscle effects may be enhanced when Lester is used in combination with niacin; a reduction in Lester dosage should be considered in this setting.

Colchicine

Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors coadministered with colchicine, and caution should be exercised when prescribing Lester with colchicine.

Warfarin

Lester had no significant pharmacokinetic interaction with R-and S-warfarin. Lester had no significant effect on prothrombin time (PT) and international normalized ratio (INR) when administered to patients receiving chronic warfarin treatment. However, patients receiving warfarin should have their PT and INR monitored when Lester is added to their therapy.

sponsored

References

DailyMed. "PITAVASTATIN CALCIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
FDA/SPL Indexing Data. "RPK779R03H: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Lester are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lester. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet

Consumer reported doses